



## PRESS RELEASE

### **BIOTEM announces an expansion of its immunoassay production & manufacturing capacities (Rapid Tests, LFIA and ELISA)**

Apprieu, June 29, 2020 – BIOTEM, a key player in the development and production of monoclonal antibodies & immunoassays (LFIA and ELISA), is pleased to announce the expansion of its **Lateral Flow / Rapid Test manufacturing capabilities** in response to a growing demand for kit production (IVD & RUO) and in order to offer its customers a fully integrated platform from the development to the industrial production of strips and cassettes.

Lateral Flow tests (immunochromatography assays) are based on the migration of antibody-conjugated nano or micro particles on strips for analyte detection in several areas.

Thanks to a significant investment in material and building, BIOTEM's teams are able to support their customers in all steps of production:

- ❖ **Mastersheet / Card Lamination**
- ❖ **Component Preparation** (antibody conjugation to tracers, buffer, etc.)
- ❖ **Optimized Spraying, Dispensing, Drying & Cutting**
- ❖ **Kit Assembly and Packaging** (strips/ cassettes)
- ❖ **Capacity: 200 k to 1,000 k tests per month**

A semi-automated platform based in France, certified **ISO 13485:2016 for IVD** with state-of-the-art equipment, allows a perfect adaptation to all needs in terms of capacity and lead times.

#### ***Contact us to learn more and discuss your industrialization program:***

BIOTEM

Parc d'activités Bièvre Dauphine

885, rue Alphonse Gourju

38140 Apprieu, France

[info@biotem.fr](mailto:info@biotem.fr)

+33 (0)4 76 65 10 91

## About BIOTEM

Expert in immunotechnology since 1980, BIOTEM is a Contract Research Organization which provides high added value services for the development of custom monoclonal antibodies and immunoassays (ELISA & LFIA). Complying with ISO 9001:2015 / ISO 13485:2016 Quality Standards, the company has been the privileged partner of more than 400 prestigious industrial and academic laboratories for their projects in fundamental research, development of improved diagnostics or generation of promising therapeutic tools.

Based on a high level of expertise and exclusive technologies, BIOTEM implements the most relevant strategies for each project according to the client's specifications. As a benefit, BIOTEM is keen to propose contracts with guaranteed results.

From the generation of original monoclonal antibodies – by Hybridoma and Phage Display technologies – through their production, characterization (affinity & specificity determination, sequencing, stability studies, etc.) to immunoassay developments, BIOTEM offers a wide range of customized services.

<https://www.biotem-antibody.com/>  
[info@biotem.fr](mailto:info@biotem.fr)

+33 (0)4 76 65 10 91